Stella Diagnostics (Stella Diagnostics) Total Assets : $0.44 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Total Assets?

Stella Diagnostics's Total Assets for the quarter that ended in Sep. 2023 was $0.44 Mil.

Total Assets is connected with ROA %. Stella Diagnostics's annualized ROA % for the quarter that ended in Sep. 2023 was -740.14%. Total Assets is also linked to Revenue through Asset Turnover. Stella Diagnostics's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Stella Diagnostics Total Assets Historical Data

The historical data trend for Stella Diagnostics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Total Assets Chart

Stella Diagnostics Annual Data

Trend

Total Assets

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Total Assets	-	0.44

Stella Diagnostics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Stella Diagnostics's Total Assets for the fiscal year that ended in . 20 is calculated as

Total Assets	=	Total Equity (A: . 20 )	+	Total Liabilities (A: . 20 )
	=	N/A	+	N/A
	=	N/A

Stella Diagnostics's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	-16.422	+	16.864
	=	0.44

Stella Diagnostics (OTCPK:SLDX) Total Assets Explanation

Total Assets is connected with ROA %.

Stella Diagnostics's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-3.264	/	( (0	+	0.441)	/ 1 )
	=	-3.264	/	0.441
	=	-740.14 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Stella Diagnostics's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0	/	( (0	+	0.441)	/ 1 )
=	0	/	0.441
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Stella Diagnostics Total Assets Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.